IMA901
- Generic Name
- IMA901
- Drug Type
- Biotech
- Background
IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
- Indication
Investigated for use/treatment in kidney cancer.
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Phase 3
Completed
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 339
- Registration Number
- NCT01265901
- Locations
- 🇷🇴
Medisprof SRL, Cluj-Napoca, Romania
🇺🇸Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, D.C., District of Columbia, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Phase 2
Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- Drug: Endoxana, IMA901, Leukine
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 68
- Registration Number
- NCT00523159
- Locations
- ðŸ‡ðŸ‡º
BAZ megyei Kórház - Urológia Osztály, Miskolc, Hungary
🇩🇪Universitätsklinikum Heidelberg - Klinik für Urologie, Heidelberg, Germany
ðŸ‡ðŸ‡ºPécs Orvostudomanyi Egyetem - Urológiai Klinika, Pécs, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath